66
Participants
Start Date
June 30, 2007
Primary Completion Date
July 31, 2010
Study Completion Date
February 28, 2011
AS703569/gemcitabine
"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
AS703569/gemcitabine
"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
Institut Jules Bordet, Brussels
Unite d'Oncologie Medicale Hopital COCHIN, Paris
Service Inter-Hospitalier de Canderologie Bichat-Beaujon (SIHC) Hopital Beaujon, Clichy
Merck KGaA, Darmstadt, Germany
INDUSTRY